Replimune Group Inc (REPL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.03B
Last updated: Nov 17, 2026 at 4:27 PM ET
Replimune Group Inc (REPL) Statistics
Replimune Group (REPL) has a market cap of $2.03B and an enterprise value of $1.84B. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 14.43% from a year earlier.
Total Valuation
Enterprise value is 9.19% below the market cap, as cash exceeds debt.
| Market Cap | $2.03B |
|---|---|
| Enterprise Value | $1.84B |
| Latest price (Nov 17, 2026) | $19.69 |
Key Dates
The next earnings report is expected on Feb 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | March |
Valuation Ratios
| Forward P/S | 59.1x |
|---|---|
| P/B Ratio | 10.1x |
Price Statistics
The stock is up 119.02% over 52 weeks and trades 31.35% above its 50-day average.
| Beta (1Y) | 0.51 |
|---|---|
| 52-Week Change | +119.02% |
| 1-Month Change | +78.19% |
| 3-Month Change | +32.95% |
| 6-Month Change | +318.94% |
| 5-Year Change | -40.33% |
| Total Return (1Y) | +119.02% |
| Total Return (3Y CAGR) | +23.70% |
| Total Return (5Y CAGR) | -10.06% |
| Return vs SPY (1Y) | +113.73% |
| Max Drawdown (1Y) | -84.16% |
| Max Drawdown (3Y) | -88.61% |
| Sharpe Ratio (1Y) | 0.45 |
| Correlation with SPY (1Y) | 0.04 |
| 50-Day Average | $14.99 |
| 200-Day Average | $10.13 |
| 52-Week Range | $1.50 to $23.54 |
| RSI (14 Days) | 58.0 |
| Average Volume (20 Days) | 3.49M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.11x current liabilities, and total debt is 0.59x shareholder equity.
| Current Ratio | 7.11x |
|---|---|
| Quick Ratio | 6.90x |
| Debt / Equity | 0.59x |
| Interest Coverage | -24.58x |
Returns and Efficiency
Return on invested capital is -65.35% and return on equity is -132.35% over the last 12 months.
| Return on Equity (ROE) | -132.35% |
|---|---|
| Return on Assets (ROA) | -72.48% |
| Return on Invested Capital (ROIC) | -65.35% |
| Return on Capital Employed (ROCE) | -82.12% |
| ROE (5Y Average) | -73.22% |
| ROA (5Y Average) | -47.22% |
Scores
REPL has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$269.73M |
| Pretax Income | -$271.58M |
| Net Income | -$271.03M |
| EBITDA | -$264.27M |
| EBIT | -$269.67M |
| Reported EPS (TTM) | -$2.79 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 54.76% of the $373.94M in total assets.
| Cash and Equivalents | $307.83M |
|---|---|
| Total Debt | $121.22M |
| Net Cash | $186.62M |
| Net Cash Per Share | $1.77 |
| Working Capital | $278.48M |
| Shareholder Equity | $204.78M |
| Book Value Per Share | $1.95 |
| Total Assets | $373.94M |
| Total Liabilities | $169.16M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $223.00K of capital spending, operating cash flow left -$245.77M of free cash flow.
| Operating Cash Flow | -$245.55M |
|---|---|
| Capital Expenditures | $223.00K |
| Free Cash Flow | -$245.77M |
| FCF Per Share | -$2.61 |
| Depreciation and Amortization | $5.41M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -45.81% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -45.81% |
Dividends and Yields
REPL does not pay a dividend. Its free cash flow yield is -11.87%.
| FCF Yield | -11.87% |
|---|---|
| Buyback Yield | -1.50% |
| Shareholder Yield | -1.50% |
Peer Position
Against 7 similar companies, REPL has the 7th highest ROIC.
ROICPeer median -17.30%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +40.00%
| ROIC | -65.35% vs -17.30% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs +40.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About REPL
What is REPL's market cap?
Replimune Group has a market cap of $2.03B. Its enterprise value, which adds debt and subtracts cash, is $1.84B.
How many shares of REPL are outstanding?
Replimune Group has 105.18M shares outstanding. The count is up 14.43% from a year earlier.
Does REPL pay a dividend?
No. Replimune Group does not pay a dividend.
How much debt does REPL have?
Replimune Group has $121.22M of total debt and $307.83M of cash and equivalents, a net cash position of $186.62M.
REPL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors